Abbott Laboratories with CE-marked diabetes tech, shares supported by analyst consensus

By Thomas Klein, Operations & Strategy desk. Reviewed prior to publication on 2026-06-23, 18:02.

Abbott Laboratories (US0028241000) expands its diabetes franchise in Europe with a new sensor-based innovation. The S&P 500 healthcare group, listed on the NYSE under the ticker ABT, has secured a CE mark for what it calls the world's first dual glucose-ketone sensing technology for people with diabetes, according to a recent company communication.

What the CE mark covers

Abbott describes the new system as a continuous sensor that can measure both glucose and ketone levels from a single wearable device, aimed primarily at people with diabetes who are at risk of ketoacidosis. The CE mark allows commercialization across the European Economic Area and generally signals that the product meets EU safety and performance requirements, as outlined in the firm's June press information on its diabetes portfolio according to a PR Newswire release.

With this step, Abbott is adding another layer to its FreeStyle Libre ecosystem, which already counts millions of users worldwide and competes directly with systems from Dexcom and Medtronic in continuous glucose monitoring. Management has repeatedly highlighted diabetes care as one of the most important growth pillars alongside diagnostics and medical devices, and the dual sensor technology fits into that strategic emphasis on high-margin, recurring-revenue platforms.

Analyst view and earnings expectations

In New York, Abbott shares are part of the S&P 500 healthcare cohort that includes peers such as Johnson & Johnson and Medtronic, and the stock is widely followed by US and European brokers. MarketBeat data point to a predominantly positive stance: a "Moderate Buy" consensus rating and an average 12-month target price that implies double-digit percentage upside from recent trading levels, with houses such as Piper Sandler and Evercore ISI among the more constructive voices on the name according to MarketBeat's analyst overview.

On the earnings side, the group last updated its guidance for the second quarter of 2026 in mid-April, setting an adjusted earnings-per-share corridor of 1.25 to 1.31 US dollars. That range sits modestly below the then prevailing consensus of around 1.34 dollars per share, pointing to a cautious stance despite robust structural demand in core franchises such as cardiovascular devices and diabetes care based on MarketBeat earnings data.

How Abbott earns its money

Abbott generates revenue across four main reporting segments: Established Pharmaceuticals, Diagnostics, Nutrition and Medical Devices, with the latter two closely linked to recurring, consumables-driven business. In diabetes, the company has built the FreeStyle Libre product line into a global continuous glucose monitoring platform, providing disposable sensors and readers for people with type 1 and type 2 diabetes in markets worldwide.

Where the Abbott share trades today

The Abbott Laboratories shares (US0028241000) most recently traded on the NYSE at around 90.34 US dollars as of 2026-06-22, 15:59 Eastern Time, according to consolidated price data.

Disclaimer: This article is for informational purposes only and does not constitute investment advice, a recommendation to buy or sell securities, or any other form of financial guidance. Investors should conduct their own research and, where appropriate, consult a licensed financial advisor.